Background
Osteoporosis is a bone disease which occurs from the imbalance between
bone formation and resorption. The incidence rate of osteoporosis is higher in women
than in men. Family history of fracture, low BMI, aging, and smoking are proven to
be risk factors for osteoporosis in women [
1]. However, a portion of the males, such as the ones with
obesity, are also at high risk for osteoporosis [
2]. Patients with osteoporosis are usually treated with calcium
supplements and hormone replacement [
3,
4]. However, therapeutic outcomes
are generally unsatisfied due to adverse side effects or poor patient compliance.
Therefore, improvement in the treatment of osteoporosis is quite critical.
Long non-coding RNAs (lncRNAs) are a subgroup of non-protein coding RNAs
with lengths longer than 200 nucleotides [
5]. Growing amounts of literature have shown that lncRNAs are key
players in many physiological and pathological processes including osteoporosis
[
6,
7]. LncRNA taurine upregulated gene 1 (TUG1) has been
demonstrated to play an effectual role in the development of human cancers
[
8,
9]. A recent study showed that the downregulation of lncRNA TUG1
participated in ankylosing spondylitis, which is an inverse pathological change of
osteoporosis [
10]. This study aimed to
analyze the involvement of TUG1 in osteoporosis and to explore its functions. We
showed that lncRNA TUG1 was upregulated in osteoporosis and regulated the
proliferation and apoptosis of osteoclasts.
Methods
Human materials
Blood (5 ml) was extracted from 98 patients with osteoporosis and
60 healthy participants who were admitted to Baoding First Central Hospital from
January 2015 to January 2018. Patients with osteoporosis were diagnosed by
dual-energy X-ray absorptiometry (T-score of < − 2.5 SD). Blood was used to
extract plasma using conventional methods. Inclusion criteria were as follows:
(1) patients with osteoclasts who were diagnosed for the first time, (2)
patients with complete medical record, and (3) patients who understood the
experimental procedure and willing to participate. Exclusion criteria were as
follows: (1) patients who were treated 3 months before admission, (2) patients
with multiple diseases, and (3) patients who failed to cooperate with
researchers. The patient group included 32 males and 66 females, and age range
from 30 to 64 years old, with a mean age of 48.2 ± 6.1 years old. Patients were
staged according to following methods: stage 1: age at 30 to 35 years old
without visible symptoms; stage 2: after age at 35 years old, bone breakdown
happens faster than bone buildup, no visible symptoms, only can be detected
through bone-density tests; stage 3: age at 45 to 55, bones become so and may
break from normal stress; stage 4: bone fractures continue, pain increases, and
may cause disability. There were 20 cases at stage I, 28 cases at stage II, 22
cases at stage III, and 28 cases at stage IV. The control group included 22
males and 38 females, and the age range from 30 to 65 years old, with a mean age
of 48.7 ± 5.7 years old. No significant differences in age and gender were found
between patient and control groups. This study passed the review of Baoding
First Central Hospital, and all participants signed informed consent.
Primary marrow–derived osteoclasts
Bone marrow osteoclast precursors were isolated from C57Bl/6 J mice
(8 weeks old, Guangdong Medical Experimental Animal Center, Guangdong, China).
Primary marrow–derived osteoclasts were generated from bone marrow osteoclast
precursors. All operations here were performed in strict accordance with the
methods described by Stiffel et al. [
11].
Real-time quantitative PCR
Total RNA was extracted from plasma using RNAzol® RT RNA Isolation
Reagent (Sigma-Aldrich). High-Capacity cDNA Reverse Transcription Kit (Thermo
Fisher Scientific) was used to performed reverse transcription. To detect the
expression of lncRNA TUG1 and PTEN mRNA, Luna® Universal One-Step RT-qPCR Kit
(NEB) was used to prepare PCR reaction systems. Primers of lncRNA TUG1 and
β-actin were designed and synthesized by GenePharma (Shanghai, China). The
expression of lncRNA TUG1 was normalized to endogenous controls β-actin using
the 2−ΔΔCT method.
Vectors, siRNAs, and cell transfection
Vectors expressing lncRNA TUG1 and empty vectors were designed and
constructed by GenePharma (Shanghai, China). LncRNA TUG1 siRNA and scrambled
negative control siRNA were also designed and constructed by GenePharma
(Shanghai, China). Lipofectamine 2000 reagent (Thermo Fisher Scientific) was
used to transfect vectors and siRNAs into primary marrow–derived osteoclasts
with vectors at a dose of 10 nM and siRNAs at a dose of 50 nM. Cells only
treated with lipofectamine 2000 reagent were control cells. Cells transfected
with empty vectors or scrambled negative control siRNA were negative control
cells.
In vitro cell proliferation assay
Expression of lncRNA TUG1 was detected at 24 h after transfection,
and cell proliferation was only detected in cases of over-expression rate of
lncRNA TUG1 reached 200% and knockdown rate reached 50%. Briefly, primary
marrow–derived osteoclasts were harvested and single-cell suspensions were
prepared with a cell density of 3 × 104 cells/ml.
Cells were transferred to a 96-well plate with 0.1 ml in each well. Cells were
cultivated under normal conditions (37 °C, 5% CO2),
followed by the addition of CCK-8 solution (10ul, Sigma-Aldrich) 24, 48, 72, and
96 h later. Cells were then cultivated for an additional 4 h, and OD values
450 nm were measured to calculate cell proliferation rate.
Cell apoptosis assay
Expression of lncRNA TUG1 was detected at 24 h after transfection,
and cell apoptosis was only detected in cases of over-expression rate of lncRNA
TUG1 reached 200% and knockdown rate reached 50%. Briefly, primary
marrow–derived osteoclasts were harvested and single-cell suspensions were
prepared with a cell density of 3 × 10
4 cells/ml
using serum-free medium. Ten-milliliter cell suspension was added into each well
of a 6-well plate, and 0.25%
trypsin digestion was performed. After cells were cultivated for 48 h,
staining with
Annexin V-FITC (Dojindo, Japan) and
propidium iodide (PI) was performed and cell apoptosis was detected by
flow cytometry.
Statistical analysis
All experiments were repeated 3 times, and the mean ± standard
deviation was calculated. The unpaired t test
was used for comparisons between 2 groups, and one-way ANOVA followed by Tukey’s
test was performed to compare 3 groups. Diagnostic values of lncRNA CASC11 for
osteoclasts were performed by the receiver operating characteristic (ROC) curve
with osteoporosis patients as true positive cases and healthy participants as
true negative cases. Differences with p <
0.05 were statistically significant.
Discussion
LncRNA TUG1 inhibition participates in ankylosing spondylitis, which is
an inverse pathological change of osteoporosis [
10], indicating the potential involvement of lncRNA TUG1 in
osteoporosis. The key finding of the present study is that lncRNA TUG1 is
upregulated in osteoporosis and lncRNA TUG1 may regulate the proliferation and
apoptosis of osteoporosis.
The development and progression of osteoporosis are accompanied by
changes in the expression pattern of a large set of lncRNAs [
7], indicating the involvement of lncRNAs in this
disease. However, most studies focused on the functions of lncRNAs in postmenopausal
osteoporosis, which is related to hormone levels [
12,
13]. Studies on
the roles of lncRNAs in general osteoporosis are rare. In a recent study, Zhang et
al. reported that lncRNA MSC-AS1 can alleviate osteoporosis by promoting osteogenic
differentiation through the upregulation of BMP2 by sponging miR-140-5p
[
14]. In another study, Zheng et
al. showed that lncRNA MALAT1 could inhibit mesenchymal stem cell osteogenic
differentiation of rat osteoporosis model [
15]. LncRNA TUG1 plays the role of oncogene or tumor suppressor
gene in different types of human cancers [
8,
16]. A recent
study showed that lncRNA TUG1 expression was inhibited in ankylosing spondylitis
[
10]. In the present study, we
first showed the upregulated expression pattern of lncRNA TUG1 in osteoporosis than
in ankylosing spondylitis people, further confirming the inverse pathological change
of osteoporosis to ankylosing spondylitis. In effect, upregulation of plasma lncRNA
TUG1 distinguished osteoporosis patients from healthy participants. Therefore,
plasma lncRNA TUG1 may serve as a potential diagnostic marker for
osteoporosis.
Osteoclasts play a key role in bone resorption [
17], which is usually accelerated in patients
with osteoporosis [
18]. Therefore,
inhibition of the proliferation of osteoclasts is considered as a promising
therapeutic target for the treatment of osteoporosis [
19,
20]. It is known
that the proliferation of osteoclasts can be regulated by lncRNAs [
21]. Phosphatase and tensin homolog (PTEN)
signaling has critical roles in the apoptosis of osteoclasts [
22]. In the present study, we showed that lncRNA
TUG1 positively regulated the proliferation of osteoclasts and negatively regulated
the apoptosis of osteoclasts through PTEN. Therefore, inhibition of lncRNA TUG1 may
serve as a promising therapeutic target for osteoporosis. However, more experimental
and clinical studies are needed to further confirm our conclusions.
Our study did not elucidate the mechanism of the actions of lncRNA TUG1
in regulating the proliferation and apoptosis of osteoclasts. However, it is known
that TUG1 can sponge miR-204-5p to promote osteoblast differentiation [
23]. It has been established that many signaling
pathways, including Runt-related transcription factors, play critical roles in
osteoblast proliferation and differentiation [
24,
25]. Our future
studies will try to characterize the potential interactions between lncRNA TUG1 and
these pathways.
Conclusion
In conclusion, lncRNA TUG1 was upregulated in osteoporosis and lncRNA
TUG1 knockdown may serve as a promising therapeutic target for osteoporosis by
inhibiting the proliferation and promoting the apoptosis of osteoclasts.
Open AccessThis article is distributed
under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction
in any medium, provided you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and indicate if
changes were made. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.